Teva Pharmaceutical Industries has decided not to launch atorvastatin, a generic version of Pfizer's Lipitor.
The decision will help Ranbaxy Laboratories and Dr Reddy's Laboratories gain larger sales of the medicine in the US, the Economic Times of India reported.
Teva Americas president and CEO William Marth was quoted by the news agency as saying that the reason for the company to take the decision was because the product was in the 30-tablet bottle.
The decision was a part of the company's strategy to optimize its resources as atorvastatin would have taken up a big portion of both its API and oral dosage formulation facility, the company said.
Currently, Ranbaxy and Watson Pharmaceuticals are the two generic companies that are selling the drug in the US along with the original drugmaker Pfizer.
